Signal or Noise: What AI in Biotech is Actually Worth

This panel focuses on where AI in biotech is creating real value across drug discovery, clinical trials, and biomanufacturing and where it is overstated. Speakers will discuss what investors and acquirers view as credible, what technical proof actually matters, and what signals separate real companies from narrative. The conversation centers on what makes an AI biotech company truly investable and usable in real clinical settings.